Primus In News
Sun Pharma partner withdraws EU application for skin cancer drug
26-06-2025
Nilaya Varma, Co-founder and Group CEO, Primus Partners, highlighted that Philogen’s withdrawal of the EU marketing application for Nidlegy marks an untimely setback for Sun Pharma. While it may not have immediate financial implications, it poses risks to the company’s long term strategic presence in Europe and Australia. This development follows closely on the heels of another disappointment as SCD44's failure triggered an 18% drop in Sun Pharma’s stock earlier this month.
Explore Related Insights
- As BluSmart runs out of charge, Tata Motors & Citroën get a shock
- Education Budget 2024: Education sector sees major boost; skill training, new institutions, school upgrades
- E-commerce policy, consumer protection rules are works in progress: DPIIT secretary
- Web3 to power India’s economic growth, expected to drive 27% of India’s incremental GDP by 2032: Study